Evaluating Current and Emerging JAK Inhibitors for Alopecia Areata: A Narrative Review

The narrative review evaluates the use of Janus kinase (JAK) inhibitors for treating alopecia areata (AA), an autoimmune condition causing hair loss. JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib have shown promise in clinical trials, with baricitinib achieving significant hair regrowth in over 1,200 participants. Ritlecitinib, approved for patients aged 12 and older, demonstrated efficacy in a trial with 718 participants. Deuruxolitinib showed promise but raised safety concerns at higher doses. Despite their potential, JAK inhibitors carry risks of serious side effects, necessitating careful monitoring. The review underscores the need for more comprehensive studies to address variability in patient response, relapse after discontinuation, and long-term safety.